XIDX
SDPC
Market cap10mUSD
Nov 12, Last price
142.00IDR
Name
Millennium Pharmacon International Tbk PT
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PT Millennium Pharmacon International Tbk is an Indonesian enterprise specializing in the wholesale and provision of a diverse range of healthcare products. This includes both prescription and over-the-counter medicines, nutritional supplements, and medical equipment. The company's comprehensive distribution channels extend to various points of sale, such as retail pharmacies, hospitals, supermarkets, and other retail establishments. As of December 31, 2021, it managed 33 regional offices strategically located across Indonesia's major islands, including Java, Bali, Sumatera, Kalimantan, and Sulawesi. Founded in 1952, the organization was originally known as PT NVPD Soedarpo Corporation Tbk before adopting its current designation, PT Millennium Pharmacon International Tbk, in February 1990. Its corporate headquarters are situated in Jakarta Selatan, Indonesia, and it operates as a subsidiary of Pharmaniaga International Corporation Sdn. Bhd.
Key people
Mohamad Muhazni bin Mukhtar
President Director · since 2012
Ahmad bin Abu Bakar
Director · since 2012
Ivan Hanafi
Independent Director · since 2018
Dian Anggreni
Legal and Corporate Secretary · since 2017
Mohamed Iqbal bin Abdul Rahman
Commissioner · since 2012
Noraini binti Mohamed Ali
Commissioner · since 2012
Izzat bin Othman
President Commissioner, Independent Commissioner · since 2015
Nyoman Kumara Rai
Independent Commissioner · since 2014
Legal address
GEDUNG BANK PANIN PUSAT LANTAI 9
JL. JENDERAL SUDIRMAN SENAYAN GELORA
JAKARTA PUSAT, JK 10270
ID
JL. JENDERAL SUDIRMAN SENAYAN GELORA
JAKARTA PUSAT, JK 10270
ID
Headquarters
GEDUNG BANK PANIN PUSAT LANTAI 9
JL. JENDERAL SUDIRMAN SENAYAN GELORA
JAKARTA PUSAT 10270
ID
JL. JENDERAL SUDIRMAN SENAYAN GELORA
JAKARTA PUSAT 10270
ID
Valuation
Title IDR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||